Moderna said on Monday its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose ...

An mRNA-based seasonal flu vaccine from Moderna was 27 percent more effective at preventing influenza infections than a ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna (NASDAQ:MRNA), on Monday, reported positive results from a late-stage study comparing its influenza vaccine candidate ...

A new slate of vaccine advisers to the US Centers for Disease Control and Prevention voted Thursday to recommend that ...

CDC advisory committee recommends thimerosal-free influenza vaccines for all adults and children, despite claims that the ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

A recombinant flu vaccine (Flublok) contains no eggs and was recently approved for use in individuals aged 9 years or older ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

Influenza significantly impacted adults aged 50 to 64 years and younger adults with chronic conditions, but risk can be reduced with RIV.

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

The votes on vaccine recommendations are the first move by the panel after Health and Human Services Secretary Robert F.